Last €102.21 EUR
Change Today -0.72 / -0.70%
Volume 0.0
4AJ On Other Exchanges
As of 2:11 AM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

alk-abello a/s (4AJ) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/28/14 - €115.86
52 Week Low
10/17/14 - €80.54
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ALK-ABELLO A/S (4AJ)

Related News

No related news articles were found.

alk-abello a/s (4AJ) Related Businessweek News

No Related Businessweek News Found

alk-abello a/s (4AJ) Details

ALK-Abelló A/S, a pharmaceutical company, engages in the research and development, production, and sale of products for the diagnosis, prevention, and treatment of allergies. The company offers allergy immunotherapy products as injections, sublingual drops, and tablets. It provides GRAZAX, a tablet-based vaccine for grass pollen allergy; SLITone, a droplet-based allergy vaccine for daily administration through a single-dose container; and Alutard SQ, a product for subcutaneous allergy vaccination. The company’s products also include JEXT, an adrenaline auto-injector used to treat acute allergic reactions; and AVANZ, an injection based immunotherapy product. Its products in pipeline comprise Grass AIT, which has completed Phase III clinical trial for the treatment of grass allergic rhinoconjunctivitis (ARC); GRAZAX that is in Phase III clinical trial for asthma prevention; Ragweed AIT, a Phase III clinical trial product for ragweed ARC; HDM AIT for the treatment of house dust mite asthma and rhinitis; and Tree AIT, a Phase II clinical trial product for the treatment of tree ARC. In addition, the company focuses on developing AIT products against Japanese cedar pollen allergy; and products for cat allergies, as well as manufactures allergen extracts for allergy testing, such as skin-prick tests. The company provides its products through distributors worldwide. ALK-Abelló A/S has partnership agreements with Merck & Co., Inc. and Torii Pharmaceutical Co., Ltd. to develop, register, and commercialize tablets in North America and Japan. The company was founded in 1923 and is headquartered in Hørsholm, Denmark.

1,796 Employees
Last Reported Date: 11/14/14
Founded in 1923

alk-abello a/s (4AJ) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

alk-abello a/s (4AJ) Key Developments

ALK-Abelló A/S Presents at SEB Nordic Seminar, Jan-09-2015 08:30 AM

ALK-Abelló A/S Presents at SEB Nordic Seminar, Jan-09-2015 08:30 AM. Venue: Hilton Copenhagen Airport Hotel, Copenhagen, Denmark.

ALK-Abelló A/S Presents at Oddo Midcap Forum, Jan-08-2015

ALK-Abelló A/S Presents at Oddo Midcap Forum, Jan-08-2015 . Venue: Lyon’s Convention Center, Lyon, France.

ALK Submits Registration Application for House Dust Mite SLIT-Tablet in Europe

ALK announced that a registration application for the house dust mite sublingual allergy immunotherapy tablet has been submitted in Europe. House dust mites are the most common cause of respiratory allergic disease, affecting an estimated 35 million adult Europeans of whom more than 3 million are poorly controlled with current standard pharmacotherapy. ALK's regulatory filing for the house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet has been accepted for review by the European health authorities via the Decentralised Procedure with Germany as the Reference Member State. The regulatory review process is expected to take around 12 months, which means that, subject to approval, the first launches could possibly take place in 2016.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4AJ:GR €102.21 EUR -0.72

4AJ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergy Therapeutics PLC 24.00 GBp 0.00
DBV Technologies SA €42.42 EUR -1.07
Merck & Co Inc $62.09 USD +0.64
Sanofi €82.36 EUR +0.10
Stallergenes SA €52.92 EUR -0.08
View Industry Companies

Industry Analysis


Industry Average

Valuation 4AJ Industry Range
Price/Earnings 33.0x
Price/Sales 2.7x
Price/Book 2.8x
Price/Cash Flow 30.8x
TEV/Sales 2.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALK-ABELLO A/S, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at